gene in patients relapsing following treatment with the BCL2 antagonist venetoclax. 66 Resistance to those brokers is connected with these mutations in all over 70% of instances, While they tend to be subclonal as well as their certain role leading to resistance ought to be proven.??? "???????????????????????????????????????????????").eighty two,ei… Read More